亚胺培南西司他丁钠美罗培南在重症肺部感染患者治疗效果及成本分析

doi:10.3969/j.issn.1006-6233.2020.12.035

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1248 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To analyze the clinical symptoms of patients with severe pulmonary infection, and to give imipenem cilastatin sodium and meropenem treatment according to the actual situation of the case, explore the final effect of the program and calculate the treatment cost. Methods: 80 patients with severe pulmonary infection admitted to our hospital from January 2017 to December 2019 were selected as the study subjects. They were divided into two groups by the red-and-blue grouping method. Patients in group A were treated with imipenem xastatin sodium, and patients in group B were treated with meropenem. The intervention effect, blood gas level, inflammatory index, bacteria culture result, drug susceptibility test result and treatment cost were compared. Results: There was no significant difference in intervention effect between group A and group B (80.0%VS85.0%) (P>, 0.05). Before intervention, there was no significant difference in blood gas index and inflammatory index between the two groups (P>0.05). After intervention, the blood gas levels of group A, PaO₂, PCO₂, PaO₂/FiO₂, PCT and CRP were all better than those of group B, with statistically significant difference (P<0.05). After treatment, the bacteria culture of group B was lower than that of group A (P<0.05). The cost-effectiveness of treatment in group B was significantly lower than that in group A (P<0.05). Conclusion: Both imipenem and cilastatin sodium and meropenem are of positive significance in the treatment of severe pulmonary infection. Meropenem is better than imipenem and cilastatin sodium in improving patients' blood gas level, immunity, and pathogen removal, reducing the treatment effect-cost, and its clinical application value is better than imipenem cilastatin sodium.

Key words： Severe pulmonary infection Imipenem and cilastatin sodium Meropenem Effect Treatment cost

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XIONG Guo
	WU Xiuqin
	HUANG Qiongxiu
	et al

Cite this article:

XIONG Guo,WU Xiuqin,HUANG Qiongxiu, et al. Analysis of Treatment Effect and Cost of Imipenem Cilastatin Sodium and Meropenem in Patients with Severe Pulmonary Infection[J]. HeBei Med, 2020, 26(12): 2083-2086.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2020.12.035 OR http://www.hbyxzzs.cn/EN/Y2020/V26/I12/2083

[1] 陈铃,雷振东,汤琼琼,等.亚胺培南西司他丁钠治疗鲍曼不动杆菌引起的重症医院获得性肺炎效果观察[J].中国乡村医药,2019,26(16):12~13.
[2] 许俊旭,王振贤,邓斌,等.海口地区二级医院重症监护病房老年重症肺炎机械通气患者的病原菌调查及防治策略[J].广西医科大学学报,2018,31(6):90~91.
[3] 王硕莹,马宏境,吴文娟,等.纤维支气管镜肺泡灌洗联合美罗培南治疗重症肺部感染的疗效研究[J].中华医院感染学杂志,2019,23(14):2099~2103.
[4] 张琳琳.亚胺培南-西司他丁钠与美罗培南对开颅术后颅内感染患者的临床疗效与安全性比较[J].抗感染药学,2019,23(6):436~437.
[5] 钱桂生,王耀丽.老年人重症肺炎诊断和治疗的新进展[J].老年医学与保健,2006,16(3):131~133.
[6] 胡基粮,胡珺.美罗培南与亚胺培南-西司他丁钠治疗老年重度医院获得性肺炎的临床疗效观察[J].航空航天医学杂志,2019,30(7):771~773.
[7] 蔡木禹,周燕琼,庄旭森,等.750例重症加强护理病房患者特殊使用级抗菌药物应用分析[J].中国医院用药评价与分析,2017,17(8):1101~1103.
[8] 周之昊.亚胺培南西司他丁钠与头孢吡肟治疗小儿重症肺炎的效果比较[J].中国当代医药,2018,23(2):1230~1231.
[9] 蔡荣.机械通气联合大剂量氨溴索治疗老年重症肺部感染患者的疗效及对血浆PCT CRP水平的影响[J].河北医学,2019,17(6):90~91.
[10] 白成,刘淑杰,李广涛.亚胺培南西司他丁在不同输注持续时间下对重症肺炎的临床疗效对比[J].中国保健营养,2017,27(4):890~891.
[11] 文艳梅,徐治波,苟冶然.老年卒中合并肺部感染患者的病原菌分布和耐药性及预防策略分析[J].实用医院临床杂志,2018,15(6):679~680.
[12] 王红霞.美罗培南与亚胺培南/西司他汀治疗重度呼吸道感染的效果比较[J].实用临床医药杂志,2019,22(23):133~135.
[13] 孙贤辉,谭成燕.亚胺培南-西司他丁钠不同输注时间对重症监护病房患者严重病原菌感染病的疗效和安全性评价[J].抗感染药学,2017,25(8):1504~1505.
[14] 高延秋,张华,刘敏,等.血必净注射液治疗重症肺炎的临床疗效和安全性评价[J].郑州大学学报(医学版),2014,28(6):837~840.
[15] 陈伦圣,李志波,尚宝明,等.亚胺培南西司他丁钠和美罗培南应用于重症肺部感染的治疗成本效果分析[J].贵州医药,2019,17(2):134~135.